CONVERGE

• Research type

  Research Study

• Full title

  A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

• IRAS ID

  1011086

• Contact name

  Ricky Thakrar

• ISRCTN Number

  ISRCTN81039232

• Research summary

  Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with about 20% being locally advanced disease Stage III (that is, large tumours or disease that has spread to nearby lymph nodes), of which approximately 80% cannot be removed by surgery. First line treatment for participants with locally advanced Stage III NSCLC has been concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT); however, this was associated with poor treatment outcomes.

  JNJ-90301900 is an intratumoural drug that is injected directly into the tumour and subsequently activated by radiation therapy to enhance tumour cell death without increasing the radiation effects in adjacent non-injected healthy tissues.

  In this study, researchers want to assess if JNJ-90301900 as a radioenhancer added to cCRT followed by cIT can improve objective response rate (ORR; that is percentage of participants in a study who have complete or partial response to treatment within a certain period) and safety of JNJ-90301900 in participants with locally advanced & unresectable NSCLC.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  25/LO/0407

• Date of REC Opinion

  4 Jul 2025

• REC opinion

  Further Information Favourable Opinion